Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$371MLATEST DEAL AMOUNT
Provider of genetic analysis products and diagnostic tests for non-invasive prenatal genetic disorders. The company provides nucleic acid analysis platform that measures genetic target material and variations.